Search Results

You are looking at 231 - 240 of 524 items for :

  • "Adjuvant therapy" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Management of Adrenocortical Carcinoma

Jonathan R. Strosberg, Gary D. Hammer, and Gerard M. Doherty

Edited by Kerrin G. Robinson

. Laparoscopic adrenalectomy for malignant disease . Lancet Oncol 2004 ; 5 : 718 – 726 . 40 Dickstein G Shechner C Arad E . Is there a role for low doses of mitotane (o,p’-DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol

Full access

Rectal Cancer

Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Anne Covey, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, Krystyna Kiel, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Sujata Rao, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, Constantinos Sofocleous, James Thomas, Alan P. Venook, and Christopher Willett

patients—a Dutch colorectal cancer group study . J Clin Oncol 2005 ; 23 : 6199 – 6206 . 94 Tepper JE O’Connell M Niedzwiecki D . Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control—final report of intergroup 0114 . J

Full access

Management of Locoregional Rectal Cancer

Christopher G. Willett

. Locoregional Rectal Cancer: What's New “The rectal cancer guidelines have been completely reworked to include the idea of mirroring the adjuvant therapies that we use in colon cancer,” said Dr. Grothey. “In the past few years, every time our committee looked

Full access

NCCN Guidelines Updates: Management of Metastatic Kidney Cancer

Eric Jonasch

is partial or radical nephrectomy or, in select patients, active surveillance. Further treatment is typically not recommended. “Following nephrectomy, adjuvant therapy for RCC has been an exercise in frustration,” he pointed out. Recent studies

Full access

Merkel Cell Carcinoma

Stanley J. Miller, Murad Alam, James Andersen, Daniel Berg, Christopher K. Bichakjian, Glen Bowen, Richard T. Cheney, L. Frank Glass, Roy C. Grekin, Dennis E. Hallahan, Anne Kessinger, Nancy Y. Lee, Nanette Liegeois, Daniel D. Lydiatt, Jeff Michalski, William H. Morrison, Kishwer S. Nehal, Kelly C. Nelson, Paul Nghiem, Thomas Olencki, Allan R. Oseroff, Clifford S. Perlis, E. William Rosenberg, Ashok R. Shaha, Marshall M. Urist, and Linda C. Wang

survival in early-stage disease—results from a review of 82 consecutive cases diagnosed between 1992 and 2004 . Ann Surg Oncol 2007 ; 14 : 1943 – 1952 . 39 Garneski KM Nghiem P . Merkel cell carcinoma adjuvant therapy: current data support

Full access

NCCN News

the latest updates to the Pancreatic Guideline and provided his perspective regarding adjuvant therapy in pancreatic disease. NCCN Breast Cancer Panel Chair Dr. Robert Carlson provided the NCCN Guidelines for Breast Cancer update and an insightful

Full access

Hereditary/Familial Ovarian Cancer: Testing Principles and Risk Management

Presented by: Leigha Senter

ovaries should be performed, which may identify occult malignancy and inform adjuvant therapy decisions. Counseling for those considering salpingo-oophorectomy should address the risks associated with surgical menopause, including cardiovascular disease

Full access

Central Nervous System Cancers

Louis Burt Nabors, Mario Ammirati, Philip J. Bierman, Henry Brem, Nicholas Butowski, Marc C. Chamberlain, Lisa M. DeAngelis, Robert A. Fenstermaker, Allan Friedman, Mark R. Gilbert, Deneen Hesser, Matthias Holdhoff, Larry Junck, Ronald Lawson, Jay S. Loeffler, Moshe H. Maor, Paul L. Moots, Tara Morrison, Maciej M. Mrugala, Herbert B. Newton, Jana Portnow, Jeffrey J. Raizer, Lawrence Recht, Dennis C. Shrieve, Allen K. Sills Jr, David Tran, Nam Tran, Frank D. Vrionis, Patrick Y. Wen, Nicole McMillian, and Maria Ho

: Chemotherapy is not a traditional mainstay of upfront treatment for low-grade gliomas. Some data support temozolomide as adjuvant therapy, and it is included as a category 2B recommendation based on nonuniform panel consensus. A phase II trial of temozolomide

Full access

Hepatobiliary Cancers, Version 2.2014

Al B. Benson III, Michael I. D’Angelica, Thomas A. Abrams, Chandrakanth Are, P. Mark Bloomston, Daniel T. Chang, Bryan M. Clary, Anne M. Covey, William D. Ensminger, Renuka Iyer, R. Kate Kelley, David Linehan, Mokenge P. Malafa, Steven G. Meranze, James O. Park, Timothy Pawlik, James A. Posey, Courtney Scaife, Tracey Schefter, Elin R. Sigurdson, G. Gary Tian, Jean-Nicolas Vauthey, Alan P. Venook, Yun Yen, Andrew X. Zhu, Karin G. Hoffmann, Nicole R. McMillian, and Hema Sundar

Cancers Local recurrence after surgery is a primary limitation for cure in patients with biliary tract cancers, which provides an important justification for the use of adjuvant therapy. Nevertheless, the role of adjuvant chemotherapy or chemoradiation

Full access

Controversies in Radiation for Upper Rectal Cancers

Emily Chan, Paul E. Wise, and A. Bapsi Chakravarthy

excision and no adjuvant therapy . J Gastrointest Surg 1999 ; 3 : 642 – 647 . 16 Guillem JG Diaz-Gonzalez JA Minsky BD . cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted . J Clin Oncol 2008 ; 26